¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"low dose rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • cumulative dose
    1. ´©Àû¿ë·® 2. ´©Àû¼±·®
  • curative dose
    1. Ä¡À¯¿ë·® 2. Ä¡À¯¼±·®
  • depth dose
    ½ÉºÎ¼±·®
  • depth dose curve
    ½ÉºÎ¼±·®°î¼±
  • dose
    1. ¿ë·®, Åõ¿©·® 2. ¼±·®, Á¶»ç·®
  • dose distribution
    ¹æ»ç¼±·®ºÐÆ÷
  • dose profile
    ¹æ»ç¼±·®Ãø¸éµµ
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • doubling dose
    ¹è°¡¼±·®
  • exit dose
    Åë°ú¼±·®
  • exposure dose
    Æø·Î¼±·®
  • effective dose
    1. À¯È¿¿ë·® 2. À¯È¿¼±·®
  • effective dose equivalent
    À¯È¿¼±·®ÇØ´ç·®
  • erythema dose
    È«¹Ý¼±·®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • onset rate
    ¹ß»ý·ü
  • operative mortality rate
    ¼ö¼ú»ç¸Á·ü
  • peak expiratory flow rate
    ÃÖ°í³¯¼û¼Óµµ, ÃÖ°íÈ£±âÀ¯¼Ó
  • perfusion rate
    °ü·ù¼Óµµ, °ü·ùÀ²
  • pregnancy rate
    Àӽŷü
  • prevalence rate
    À¯º´·ü
  • pulse rate
    ¸Æ¹Ú¼ö
  • relaxation rate
    À̿Ϸü
  • respiratory rate
    È£Èí¼öÈ£Èí·ü
  • response rate
    ¹ÝÀÀ·ü
  • standardized death rate
    Ç¥ÁØÈ­»ç¸Á·ü
  • survival rate
    »ýÁ¸·ü
  • tidal rate
    È£Èí¼ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • depth dose curve
    ½ÉºÎ¼±·®°î¼±
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • percentage depth dose curve
    ½ÉºÎ¼±·®¹éºÐÀ²°î¼±
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • dose
    ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
  • depth dose
    ½ÉºÎ¼±·®
  • dose distribution
    ¹æ»ç¼±·®ºÐÆ÷
  • dose profile
    ¹æ»ç¼±·®Ãø¸éµµ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • doubling dose
    ¹è°¡¼±·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • erythema dose
    È«¹Ý¼±·®
  • exit dose
    Åë°ú¼±·®
  • exposure dose
    Æø·Î¼±·®
  • fatal dose
    Ä¡»ç¿ë·®, Ä¡»ç¼±·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • priming dose
    ÃÊȸÇ׿øÀڱط®.(¾à¸®)ÃÊȸ(¿ë)·®.
  • priming dose
    ÃÊȸÇ׿øÀڱط®.[¾à¸®]ÃÊȸ(¿ë)·®, ºÎÇÏ(¿ë)·®.
  • quasithreshold dose, Dq
    ÁØÇѰ輱·®
  • radiation absorbed dose
    ¹æ»ç¼±Èí¼ö¼±·®
  • radiation dose (rad)
    ¹æ»ç¼±·®
  • reacting dose
    ¹ÝÀÀ·®(ÚãëëåÖ).
  • reference dose
    ±âÁؼ±·®
  • relative dose
    ºñ±³ Á¶»ç·®
  • BMR=£¾basal metabolic rate
    ±âÃÊ´ë»çÀ²
  • GFR => glomerular filtration rate
    »ç±¸Ã¼¿©°úÀ²
  • GFR= glomerular filtration rate
    »ç±¸Ã¼(ÞêϹô÷)°Å¸§·ü(×È).
  • GFR= glomerular filtration rate
    »ç±¸Ã¼°Å¸§·ü.
  • Heart rate
    ½É¹Ú¼ö(ãýÚÑâ¦)
  • MVR=£¾maximus voiding rate
    ÃÖ´ë¹è´¢À².
  • Westergren sedimentation rate
    ¿þ½ºÅͱ׷»Ä§°­¼Óµµ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • low echo area
    Àú¿¡ÄÚ ±¸¿ª
  • low electron density
    ÀúÀüÀڹеµ(î¸ï³í­ ÚËöô).
  • low fat diet
    ÀúÁö¹æ½Ä.
  • low fever
    ¹«·Â¿­(Ùíæ³æð).
  • low field MR scanner
    ÀúÀÚÀå ÀÚ±â°ø¸í½ºÄ³³Ê
  • low forceps
    ÀúÀ§°âÀÚ(î¸êÈÌÆí­).
  • low forceps operation
    (žư¡ ±Ø»óµ¹±â ¾Æ·¡¿¡ ÀÖÀ» °æ¿ìÀÇ), Àú À§°âÀÚ¼ö¼ú(î¸êÈÌÆí­â¢âú).
  • low frequency
    ÀúÁÖÆÄ
  • low frequency deafness
    ÀúÁ֯ijó, ÀúÁÖÆÄ±Í¸ÔÀ½
  • low frequency therapeutic apparatus
    ÀúÁÖÆÄÄ¡·á±â
  • low frequency therapeutic apparatus
    ÀúÁÖÆÄÄ¡·á±â(î¸ñ²÷îö½èþÐï).
  • low frequency transduction
    Àúºóµµ ÇüÁúµµÀÔ
  • low fusing porcelain
    Àú¿ëµµÀç.
  • low heat
    Àú¿­.
  • low intensity void in proton flow
    ¾ç¼ºÀÚ È帧ÀÇ Àú°­µµ ¼Ò½Ç
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • median effective dose
    Á¤Áß À¯È¿·®(ïáñéêóüùÕá)
  • median hemolytic dose
    Á¤Áß ¿ëÇü·®(ïáñééÁúìÕá)
  • median immunizing dose
    Á¤Áß ¸é¿ª·®(ïáñéØóæµÕá)
  • median infectious dose
    Á¤Áß °¨¿°·®(ïáñéÊïæøÕá)
  • median lethal dose
    Á¤Áß Ä¡»ç·®(ïáñéöÈÞÝÕá)
  • median paralysis dose
    Á¤Áß ¸¶ºñ·®(ïáñ騫ÝöÕá)
  • median tissue culture dose
    Á¤ÁßÁ¶Á÷¹è¾ç·®(ïáñéðÚòÄÛÆå×Õá)
  • median toxic dose
    Á¤Áß µ¶¼º·®(ïáñéÔ¸àõÕá)
  • minimum hemagglutinating dose
    ÃÖ¼ÒÇ÷±¸ÀÀÁý·®(õÌá³úìϹëêó¢Õá)
  • minimum hemolytic dose
    ÃÖ¼Ò¿ëÇ÷·®(õÌá³éÁúìÕá)
  • minbimum lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝÕá)
  • permissible dose
    Çã¿ë·®(úÉé»Õá)
  • priming dose
    ÀÏÂ÷󸮿뷮(ìéó­ô¥×âéÄÕá)
  • radiation absorbed dose
    ¹æ»ç¼± Èí¼ö·®(Û¯ÞÒàÊýåâ¥Õá)
  • radiation dose
    ¹æ»ç¼±·®(Û¯ÞÒàÊÕá)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
NSD Nairobi sheep disease; neonatal staphylococcal disease; neurosecretory dysfunction; night sleep depr...
TCD tapetochoroidal dystrophy; T-cell depletion; thermal conductivity detector; tissue culture dose; tra...
ACR abnormally contracting region; absolute catabolic rate; acriflavine; adenomatosis of colon and rectu...
CR calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio...
MR Maddox rods; magnetic resistance; magnetic resonance; mandibular reflex; mannose-resistant; may repe...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
DI Dose Intensity
DMF Dose Modifying Factor
DRF Dose Reduction Factor
DAP Dose area product
DLT Dose limiting toxicities
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dose-effect relationship
    ¼±·® ¿µÇâ °ü°è
  • dose-equivalent limit
    ¼±·® ´ç·® Çѵµ
  • dose-response curve
    ¿ë·® ¹ÝÀÀ °î¼±
  • dose-volume histogram
    ¼±·® üÀû È÷½ºÅä±×¶÷, ¼±·® üÀûÇ¥
  • effective dose 50%
    Áß°£ À¯È¿·®, 50% À¯È¿·®
    µ¿¹°¿¡ µ¶¼Ò³ª ¾à¹° Åõ¿© ½Ã, 50%ÀÇ µ¿¹°¿¡¼­ À¯È¿ÇÏ´Ù°í ÃßÁ¤µÇ´Â ¿ë·®.
  • equivalent dose
    µî°¡ ¼±·®
  • equivalent uniform dose
    µî°¡ ±ÕÁú ¼±·®
  • erythema dose
    Èï¹Ý ¼±·®
  • exposure dose
    Á¶»ç·®
  • high dose tolerance
    °í¿ª ¿ªÄ¡
  • immunizing dose
    ¸é¿ª·®
  • intoxicating dose
    Áßµ¶·®, Áßµ¶ ¼±·®
  • least fatal dose
    ÃÖ¼Ò Ä¡»ç·®
    ¾àÁ¦ÀÇ ¿ë·®À» °áÁ¤ÇÏ´Â ½ÇÇè¿¡¼­ 100¸í Áß 1¸íÀÌ¶óµµ »ç¸ÁÇÏ´Â ¹Ù·Î Á÷ÀüÀÇ ¿ë·®.
  • loading dose
    ºÎÇÏ ¿ë·®, ºÎÇÏ·®
  • maintenance dose
    À¯Áö·®, À¯Áö ¿ë·®
    ÀÏÁ¤ÇÑ »óŸ¦ À¯ÁöÇϱâ À§Çؼ­ ÇÊ¿äÇÑ ¾àÁ¦ÀÇ Åõ¿©·®.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
low tension glaucoma Optic nerve atrophy and excavation with typical field defects of glaucoma but without abnormal increase in intraocular pressure.
(05 Mar 2000)
low tone deafness Inability to hear low notes or frequencies.
(05 Mar 2000)
low wine The first weak distillate obtained from the mash in the process of making whisky.
(05 Mar 2000)
lymphoma, low-grade One of the three major prognostic groupings for non-hodgkin lymphomas as proposed in the working formulation of the non-hodgkin's lymphoma pathologic classification project sponsored by the national cancer institute (1981). Lymphomas falling within this group have a relatively favourable survival potential.
(12 Dec 1998)
absorbed dose The amount of energy absorbed per unit mass of irradiated material at the target site; in radiation therapy, the former unit for absorbed dose is the rad; the current (S.I.) unit is the gray.
(05 Mar 2000)
air dose The radiation dose, expressed in roentgens, delivered at a point in free air.
Synonym: air dose.
(05 Mar 2000)
bone marrow dose The cumulative dose to the blood-forming organ from therapeutic or nuclear fallout irradiation; the presumed leukemogenic dose.
(05 Mar 2000)
booster dose A dose given at some time after an initial dose to enhance the effect, said usually of antigens for the production of antibodies.
(05 Mar 2000)
breast dose in mammography <radiology> 180 mrad / view -- mid-breast dose, guideline: less than 1 rad for 2-view exam
(12 Dec 1998)
maintenance dose In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
genetically significant dose <physics, radiobiology> The genetically significant dose is that which, if received by every member of the population, would be expected to produce the same genetic injury to the population as do the actual doses received by the individuals irradiated.
Thus, the genetically significant dose is the dose equivalent to the gonads weighted for the age and sex distribution in those members of the irradiated population expected to have offspring. The genetically significant dose is expressed in sieverts (or rem).
Acronym: GSD
(06 Aug 1998)
maximal dose <pharmacology> The largest amount of a drug or physical procedure that an adult can take with safety.
(05 Mar 2000)
maximum permissible dose <radiobiology> Defined by the International Commission on Radiological Protection as the greatest dose of radiation which, in the light of present knowledge, is not expected to cause detectable bodily injury to a person at any time during his lifetime.
This dose has been reduced with each Commission report. The MPD is given in terms of acute or chronic exposure of the whole body or of organs, systems, or regions of the body, and differs for persons who are occupationally exposed versus the public at large.
(05 Mar 2000)
median effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
gonadal dose The exposure dose to the male or female gonad, usually from incidental secondary radiation in diagnostic or therapeutic irradiation, or from whole-body irradiation.
Synonym: gonadal dose.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • exchange rate
    ȯÀ²
  • fatality rate
    »ç¸Á·ü
  • fixed exchange rate(system)
    °íÁ¤È¯½Ã¼¼(Á¦)
  • flat rate
    °íÁ¤(Á¤¾×)¿ä±Ý
  • floating exchange rate system
    º¯µ¿ ȯÀ²Á¦
  • floating rate
    ÀÚÀ¯ º¯µ¿ ½Ã¼¼;¼±Çϼ¼
  • forward rate
    (¿Ü±¹È¯ÀÇ) ¼±¹° ½Ã¼¼
  • freight rate
    ¿îÀÓ·ü Àå
  • fuel rate
    Ãʰ£ ¿¬·á ¼ÒºñÀ²
  • interest rate
    ±Ý¸®ÀÌÀ²
  • kill rate
    (ÀüÀï,Æøµ¿ µîÀÇ)»ì»ý·ü 9
  • milline rate
    1milline ´çÀÇ ±¤°í·á
  • minimum lending rate
    (¿µ)(À×±Û·£µå ÀºÇàÀÇ) ÃÖÀú ´ëÃ⠱ݸ®
  • poor rate
    ±¸ºó¼¼
  • prime rate
    (¹Ì±¹ ÀºÇàÀÌ 1·ù ±â¾÷¿¡ Àû¿äÇÏ´Â)Ç¥ÁØ ±Ý¸®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á